EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?

Stuart McPherson iD, Jessica K Dyson, Laura Jopson, Steven Masson iD, Preya Patel, Quentin M Anstee iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18061 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Stuart McPherson and 5 co-authors. Institution: Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK. Major MEDLINE topics: Liver Cirrhosis, Elasticity Imaging Techniques. Cited 7 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY 4.0). Funded by: Innovative Medicines Initiative (IMI2), European Union, EFPIA, Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Sequential use of non‐invasive fibrosis tests (NITs) to identify patients with advanced hepatic fibrosis is recommended. However, it remains unclear how reliable clinicians are staging liver fibrosis using combinations of NITs.

Aim

Our aim was to assess concordance between NIT‐based ‘clinician fibrosis assessment (CFA)’ and histology in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) and compare this with established algorithmic approaches.

Methods

Six experienced hepatologists independently staged 230 MASLD patients for advanced fibrosis (F0‐2 vs F3‐4) using FIB‐4, FIB‐4+ELF, FIB‐4+ vibration controlled transient elastography (VCTE; Fibroscan™) and FIB‐4+ELF+VTCE. Concordance between histology and CFA or algorithmic approaches were assessed.

Results

A total of 230 patients were included (median age 54 [22–78] years; 55% female; median FIB‐4 1.21 [IQR: 0.78–1.91]; ELF 9.3 [IQR: 8.6–10.2]; VCTE 9.4 [IQR: 6.3–14.3]; 41% F0‐1, 22% F2, 21% F3 and 16% F4). Overall, area under the receiver operator curves for histologic F3‐4 for the raw tests were 0.84 for FIB‐4, 0.86 for ELF and 0.86 for VCTE. Concordance between the hepatologists was good (FIB4, κ = 0.64; FIB‐4+ELF, κ = 0.70; FIB‐4+VCTE, κ = 0.69; FIB‐4+ELF+VCTE, κ = 0.70). Concordance between individual CFA and histology was variable, which was reflected in variability in sensitivity (44%–84%) and specificity (76%–94%). Concordance with histology was better when clinicians used NIT combinations. Purely algorithmic approaches, particularly sequential use of FIB‐4 then VCTE, tended to perform better than the CFA.

Conclusions

Adhering to the recommended algorithmic approaches using NITs to stage fibrosis tended to perform more accurately than less‐structured clinician NIT‐based assessments conducted by experienced hepatologists.

Subjects

MeSH terms (MEDLINE)

Liver CirrhosisElasticity Imaging TechniquesHumansFemaleMaleMiddle AgedAgedAdultSeverity of Illness IndexFatty LiverYoung AdultAlgorithmsBiopsyNon-alcoholic Fatty Liver DiseaseLiver

Authors and institutions

  • Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
  • Newcastle NIHR Biomedical Research Centre, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

ORCID profiles: Stuart McPherson, Steven Masson, Quentin M Anstee

Funding

  • Innovative Medicines Initiative (IMI2), European Union
  • EFPIA
  • Medical Research Council
  • European Federation of Pharmaceutical Industries and Associations

Cite

APA

McPherson, S., Dyson, J. K., Jopson, L., Masson, S., Patel, P., & Anstee, Q. M. (2024). How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18061

Vancouver

McPherson S, Dyson JK, Jopson L, Masson S, Patel P, Anstee QM. How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18061

BibTeX
@article{McPherson2024,
  author = {McPherson, Stuart and Dyson, Jessica K and Jopson, Laura and Masson, Steven and Patel, Preya and Anstee, Quentin M},
  title = {How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18061}
}
Start for free →